title: Beta-adrenergic blockade does not prevent polycythemia or decrease in plasma volume in men at 4300 m altitude.
abstract: When humans ascend to high altitude (ALT) their plasma volume (PV) and total blood volume (BV) decrease during the first few days. With continued residence over several weeks, the hypoxia-induced stimulation of erythropoietin increases red cell production which tends to restore BV. Because hypoxia also activates the beta-adrenergic system, which stimulates red blood cell production, we investigated the effect of adrenergic beta-receptor inhibition with propranolol on fluid volumes and the polycythemic response in 11 healthy unacclimatized men (21-33 years old exposed to an ALT of 4300 m (barometric pressure 460 Torr) for 3 weeks on Pikes Peak, Colorado. PV was determined by the Evans blue dye method (PVEB), BV by the carbon monoxide method (BVCO), red cell volume (RCV) was calculated from hematocrit (Hct) and BVCO, and serum erythropoietin concentration ([EPO]) and reticulocyte count, were also determined. All determinations were made at sea level and after 9-11 (ALT-10) and 19-20 (ALT-20) days at ALT. At sea level and ALT, six men received propranolol (pro, 240 mg x day[-1]), and five received a placebo (pla). Effective beta-blockade did not modify the mean (SE) maximal values of [EPO] [pla: 24.9 (3.5) vs pro: 24.5 (1.5) mU x ml(-1)] or reticulocyte count [pla: 2.7 (0.7) vs pro: 2.2 (0.5)%]; nor changes in PVEB [pla: -15.8 (3.8) vs pro: -19.9 (2.8)%], RCVCO [pla: +7.0 (6.7) vs pro: + 10.1 (6.1)%], or BVCO [pla: -7.3 (2.3) vs pro: -7.1 (3.9)%]. In the absence of weight loss, a redistribution of body water with no net loss is implied. Hence, activation of the beta-adrenergic system did not appear to affect the hypovolemic or polycythemic responses that occurred during 3 weeks at 4300 m ALT in these subjects.
authors.affiliation: Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver 80262, USA.
authors.forename: R F
authors.initials: RF
authors.lastname: Grover
authors.forename: M A
authors.initials: MA
authors.lastname: Selland
authors.forename: R G
authors.initials: RG
authors.lastname: McCullough
authors.forename: T E
authors.initials: TE
authors.lastname: Dahms
authors.forename: E E
authors.initials: EE
authors.lastname: Wolfel
authors.forename: G E
authors.initials: GE
authors.lastname: Butterfield
authors.forename: J T
authors.initials: JT
authors.lastname: Reeves
authors.forename: J E
authors.initials: JE
authors.lastname: Greenleaf
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000531:Altitude; D001810:Blood Volume; D004920:Erythropoiesis; D004921:Erythropoietin / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D008297:Male; D010953:Plasma Volume / Q000187:drug effects*; D011086:Polycythemia / Q000209:etiology* / Q000517:prevention & control*; D011433:Propranolol / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D004921:Erythropoietin; D011433:Propranolol